No Longer Available EXPANDED_ACCESS NCT03564964

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)

An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study

Sponsor: Suven Life Sciences Limited

Conditions Alzheimer Disease Cognition Disorders Dementia

Interventions SUVN-502

Updated 6 times since 2018 Last updated: Sep 25, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Alzheimer Disease and Cognition Disorders, this trial is ongoing. The trial is conducted by Suven Life Sciences Limited and has accumulated 6 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

No Longer Available
Jul 2024 — Sep 2024 [monthly]

No Longer Available
Jan 2021 — Jul 2024 [monthly]

No Longer Available
Oct 2020 — Jan 2021 [monthly]

No Longer Available

Status: Available → No Longer Available
Oct 2019 — Oct 2020 [monthly]

Available

▶ Show 1 earlier version

Jul 2018 — Oct 2019 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Suven Life Sciences Limited

Data source: Suven Life Sciences Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.